China's NMPA Accepts BLA for LEROCHOL® to Treat High Cholesterol

Everest Medicines has announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for LEROCHOL® (lerodalcibep). This PCSK9 inhibitor is proposed as a subcutaneous treatment to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia. This acceptance marks a key step towards potential market approval in China.